Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Three patients with papillary renal cell carcinoma (PRCC) and MET aberrations had partial responses with durations from 39 to 147 weeks.
|
30952639 |
2019 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
|
30466410 |
2018 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Both primary tumors and metastases expressed typical markers of pRCC and carried the same activating MET mutation as the parental tumor.
|
27715452 |
2017 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Results Of 109 patients treated, PRCC was MET driven in 44 (40%) and MET independent in 46 (42%); MET status was unknown in 19 (17%).
|
28644771 |
2017 |
Papillary Renal Cell Carcinoma
|
0.800 |
SomaticCausalMutation
|
disease |
ORPHANET |
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
|
26536169 |
2016 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
|
26718059 |
2016 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two PRCC PDX models were identified and MET mutation status and copy number determined.
|
25779944 |
2015 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases.
|
26052049 |
2015 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Finally, germline mutations of the c-Met gene have been proposed as the first predictor of response to targeted therapies in papillary renal cell carcinoma.
|
24495452 |
2015 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Overall, this study provides evidence that Chromosome 7 gain drives MET gene copy number increase in PRCC tumors, and appears to subsequently lead to an increase in MET protein overexpression in these tumor cells.
|
26636767 |
2015 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
|
24812413 |
2014 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC).
|
23213094 |
2013 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
|
18055465 |
2008 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The MET oncogene was causally involved in the pathogenesis of a rare tumor, i.e., the papillary renal cell carcinoma, in which activating mutations, either germline or somatic, were identified.
|
16651428 |
2006 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations affecting the MET receptor tyrosine kinase are present in several types of human cancer, particularly in papillary renal cell carcinoma.
|
15767811 |
2005 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
The MET oncogene drives a genetic programme linking cancer to haemostasis.
|
15772665 |
2005 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
|
15557554 |
2004 |
Papillary Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Alterations of known genes in PRCC include missense mutations in the MET oncogene (7q31) and rare translocations fusing TFE3 at Xp11.2 with a variety of other loci.
|
12213728 |
2002 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
|
10433944 |
1999 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
|
9140397 |
1997 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
Activating mutations for the met tyrosine kinase receptor in human cancer.
|
9326629 |
1997 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
CLINGEN |
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.
|
1917129 |
1991 |
Papillary Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
Papillary Renal Cell Carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|